Insmed

Partnerships

Join our fearless fight

Insmed is a global biopharmaceutical company that invests in scientific and commercial innovation to transform the lives of patients with serious and rare diseases.

We have expertise in all stages of development, from concept to market, and industry-leading global commercial capabilities in the U.S., major EU markets, and Japan

Insmed’s first commercialized product was a top ten non-oncology rare disease launch (based on first-year sales) in the U.S. We’re building on that success in the EU and Japan and advancing a robust pipeline of investigational therapies aimed at addressing a range of serious diseases.

For further information on our clinical development programs, view the following resources:

Business development areas of interest

We recognize that global experts in the biopharmaceutical and academic fields who share our profound sense of urgency and patient focus can contribute to our goal of bringing life-altering therapies to patients with serious and rare diseases.

We actively seek business development opportunities in the following areas:

Clinical and commercial-stage assets in respiratory, immunology, inflammation, neurology, rare cardiovascular, metabolic, monogenic ocular, and rare diseases

Research, development, and commercialization collaborations that are strategically aligned with our existing portfolio and the therapeutic areas noted

Technology platforms and programs (<12 months to IND) that are complementary to our research capabilities and further advance our research efforts into breakthrough science

While we are primarily interested in global in-licensing and acquisition opportunities, we would consider high-potential regional opportunities that leverage our commercialization expertise in the U.S., major EU markets, and Japan. We are also interested in exploring in-licensing assets from China and South Korea, with an emphasis on advanced, derisked programs with clinically validated targets that may offer improved pharmacokinetics, safety, and efficacy profiles, or alternative routes of administration.

We are not seeking opportunities in oncology, neuro-psych, or obesity or in modalities using re-purposed medicines, 505b(2), products with modest differentiation from Standard of Care, generics and biosimilars, or cosmetic/OTC products.

Contact us

Our Business Development team is based in the U.S. and UK and covers opportunities globally. We regularly attend major partnering meetings. Reach out to us through the form below to schedule time to meet or for any partnership inquiries.